

HR 7515

Infectious Disease Therapies Research and Innovation Act of 2022

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Taxation

Introduced: Apr 14, 2022

Current Status: Referred to the House Committee on Ways and Means.

Latest Action: Referred to the House Committee on Ways and Means. (Apr 14, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/7515>

Sponsor

Name: Rep. Kelly, Mike [R-PA-16]

Party: Republican • **State:** PA • **Chamber:** House

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Buchanan, Vern [R-FL-16]	R · FL		Apr 14, 2022
Rep. Wenstrup, Brad R. [R-OH-2]	R · OH		Apr 14, 2022

Committee Activity

Committee	Chamber	Activity	Date
Ways and Means Committee	House	Referred To	Apr 14, 2022

Subjects & Policy Tags

Policy Area:

Taxation

Related Bills

No related bills are listed.

Summary (as of Apr 14, 2022)

Infectious Disease Therapies Research and Innovation Act of 2022

This bill exempts from the definition of *passive activity*, for purposes of the passive loss tax rules, any qualified medical research activity of a specified medical research small business pass-thru entity.

The bill defines *specified medical research small business pass-thru entity* as any domestic pass-thru entity if more than 80% of such entity's expenditures on research are paid or incurred in connection with qualified medical research activities and the gross receipts of such entity for the taxable year are less than \$1 million.

Actions Timeline

- **Apr 14, 2022:** Introduced in House
- **Apr 14, 2022:** Referred to the House Committee on Ways and Means.